HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Would Explore Where No Other Firm Has Gone Before With Lipitor Switch

This article was originally published in The Tan Sheet

Executive Summary

The degree of difficulty is tremendous for the first novel switch FDA approves, but it would provide a template others can follow. FDA’s interest in fostering innovative OTC switches could work in favor of proposals to make currently Rx ingredients indicated for a chronic condition available nonprescription.

You may also be interested in...



US FDA Advisory Committee Members Say Votes Should More Directly Affect Agency Decisions

Survey of advisory committee members finds many believe an overwhelmingly negative vote should prevent a product approval. Survey was prompted by FDA accelerated approval of Alzheimer’s disease treatment Aduhelm despite overwhelming committee rejection.

Room For Innovative Switches Could Lurk In Existing FDA Framework

When firms suggest submitting switch NDAs for “something that would be worth engaging on, we’re not going to tell you no,” says FDA nonprescription drug program chief Theresa Michele.

In $4.4 Trillion ‘Global Wellness Economy’ Of 2020, Supplement Sales Accounted For $137.7 Billion

Global Wellness Institute’s vitamins and supplements, healthy-labeled foods and beverages and weight loss products and services overall showed 3.6% sales growth to $945bn from 2019 to 2020, according to institute’s latest report.

Topics

Related Companies

UsernamePublicRestriction

Register

RS123701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel